Amarin Corp Plc (AMRN)

[Jasbg]

LM, A question from a non bio / med knowledgeable person ?
-------------------

Would it be possible (any precedent) to contact participants in the R-I trial - answering questions on their later dementive status ?

A portion will be dead - but R-I status is still only some 5 years away (2018) - the 5 years that have passed, might actually be a positive in this context - of 'following up on the later effect of Vascepa on the brain - in the big group of people.

Recognize that there will be a number of other challenges on the way - (some have stopped taking Vascepa in the meantime etc. ).

But feed the right data, from a group this big (even after eliminating all not statistically relevant participants) - into modern computer calculations - results would be extremely exciting to 'follow' - given the weight of the big double blinded R-I trial.
---------------------

If something like the above presented idea were possible - would be accepted by FDA as 'trustworthy relevant data' - in the fight against AZ and dementia prolems' - it could to some extent 'compensate' (in lack of a better word) - the totally unforseen / meaningless / 'based on fraud' - Judge Du ruling - back in early 2020 🙂